Full text

Turn on search term navigation

© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Infection with the intracellular bacterium Coxiella (C.) burnetii can cause chronic Q fever with severe complications and limited treatment options. Here, we identify the enzyme cis-aconitate decarboxylase 1 (ACOD1 or IRG1) and its product itaconate as protective host immune pathway in Q fever. Infection of mice with C. burnetii induced expression of several anti-microbial candidate genes, including Acod1. In macrophages, Acod1 was essential for restricting C. burnetii replication, while other antimicrobial pathways were dispensable. Intratracheal or intraperitoneal infection of Acod1−/− mice caused increased C. burnetii burden, weight loss and stronger inflammatory gene expression. Exogenously added itaconate restored pathogen control in Acod1−/− mouse macrophages and blocked replication in human macrophages. In axenic cultures, itaconate directly inhibited growth of C. burnetii. Finally, treatment of infected Acod1−/− mice with itaconate efficiently reduced the tissue pathogen load. Thus, ACOD1-derived itaconate is a key factor in the macrophage-mediated defense against C. burnetii and may be exploited for novel therapeutic approaches in chronic Q fever.

Details

Title
Macrophages inhibit Coxiella burnetii by the ACOD1-itaconate pathway for containment of Q fever
Author
Kohl, Lisa 1 ; Md Nur A Alam Siddique 1   VIAFID ORCID Logo  ; Bodendorfer, Barbara 1 ; Berger, Raffaela 2 ; Preikschat, Annica 1   VIAFID ORCID Logo  ; Daniel, Christoph 3 ; Ölke, Martha 1 ; Liebler-Tenorio, Elisabeth 4 ; Schulze-Luehrmann, Jan 1 ; Mauermeir, Michael 1 ; Kai-Ting, Yang 5   VIAFID ORCID Logo  ; Hayek, Inaya 1 ; Szperlinski, Manuela 1 ; Andrack, Jennifer 6 ; Schleicher, Ulrike 7 ; Bozec, Aline 8   VIAFID ORCID Logo  ; Krönke, Gerhard 8 ; Murray, Peter J 9   VIAFID ORCID Logo  ; Wirtz, Stefan 10 ; Yamamoto, Masahiro 11 ; Schatz, Valentin 12 ; Jantsch, Jonathan 12 ; Oefner, Peter 2 ; Degrandi, Daniel 13 ; Pfeffer, Klaus 13 ; Mertens-Scholz, Katja 6 ; Rauber, Simon 5   VIAFID ORCID Logo  ; Bogdan, Christian 7   VIAFID ORCID Logo  ; Dettmer, Katja 2 ; Lührmann, Anja 7   VIAFID ORCID Logo  ; Lang, Roland 7   VIAFID ORCID Logo 

 Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany 
 Institute of Functional Genomics, University of Regensburg, Regensburg, Germany 
 Department of Nephropathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany 
 Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Jena, Germany 
 Department of Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany 
 Institute of Bacterial Infections and Zoonoses, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Jena, Germany 
 Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany; Medical Immunology Campus Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany 
 Department of Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Medical Immunology Campus Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany 
 Max Planck Institute for Biochemistry, Martinsried, Germany 
10  Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Medical Immunology Campus Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany; Department of Medicine 1, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany 
11  Immunology Frontier Research Center, Osaka University, Osaka, Japan 
12  Institute of Clinical Microbiology, University Hospital Regensburg, Regensburg, Germany 
13  Institute of Medical Microbiology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany 
Section
Articles
Publication year
2023
Publication date
Feb 2023
Publisher
EMBO Press
ISSN
17574676
e-ISSN
17574684
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2774058158
Copyright
© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.